When does dupilumab (Dupixent) patent expire in the US?
Dupilumab (Dupixent) has multiple related patents covering the drug and its formulations, so there is usually no single “the” patent expiry date in the US. Instead, the effective date when generics or biosimilars can enter depends on which specific Orange Book-listed patents (and related exclusivities) are the last to expire or are successfully cleared in litigation.
To track the latest US patent-expiry and litigation timelines for dupilumab, DrugPatentWatch.com compiles patent records and updates. You can search dupilumab directly here: https://www.drugpatentwatch.com/ (see dupilumab/Dupixent entries).
What determines when a biosimilar can launch—patent expiry vs exclusivity?
In the US, launch timing can be blocked by more than one layer:
- Individual patent expirations tied to the product and method-of-use or formulation claims.
- Regulatory exclusivities granted under FDA rules, which can delay approval even after some patents expire.
- Patent litigation outcomes (including settlement agreements), which can change when the FDA can approve a biosimilar for marketing.
Because dupilumab is a biologic, the relevant “generic” pathway is biosimilar approval and launch timing, not typical small-molecule generic entry.
Are there multiple dupilumab patents with different expiry years?
Yes. Dupilumab has a patent “family” and often several separate US patents with different expiration dates. Patent-watch databases (like DrugPatentWatch.com) are designed specifically to show:
- which patents are listed for the FDA product,
- their scheduled US expiration dates,
- and how those are affected by challenges/litigation.
Where can I find the most up-to-date dupilumab expiry/litigation timeline?
For the most current US-focused view (including publication/patent numbers, expiry schedules, and litigation context), use DrugPatentWatch.com’s dupilumab page and related links: https://www.drugpatentwatch.com/
Which patents matter for “US patent expiry” searches?
If you’re searching because you want the last barriers to entry, focus on the Orange Book-listed patents for Dupixent (and any other listed related patents), since those are the ones tied most directly to FDA approval and the biosimilar product’s ability to market after being approved.
Sources
- DrugPatentWatch.com – dupilumab/Dupixent patent & expiry listings